ArticleGastroenterology2026
Inflammation-Induced Claudin-2 Up-Regulation Limits Pancreatitis Development by Enhancing Pancreatic Ductal Transport.
Article in Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
26 authors.
Funding
Abstract
BACKGROUND &
aimsPancreatitis is influenced by environmental and genetic factors. Genome-wide association studies identified polymorphisms at the X-linked CLDN2 locus as risk factors for chronic pancreatitis. CLDN2 encodes claudin-2 (CLDN2), a paracellular cation-selective channel at tight junctions. However, its role in pancreatitis susceptibility remains unclear. We aimed to determine the role of CLDN2 in pancreatitis onset and progression.
methodsHuman pancreatic tissue, pancreatitis mouse models, pancreatic ductal epithelial organoids, and isolated mouse pancreatic ducts were used. CLDN2 expression, its regulation by cytokines, and its impact on pancreatic inflammation, fibrosis, and ductal fluid transport were assessed.
resultsCLDN2 was up-regulated in human chronic pancreatitis and in both caerulein-induced and T7D23A mutation mouse models. Interferon-γ increased CLDN2 expression at RNA and protein levels in organoids and mouse pancreas. Ifng knockout (KO) mice showed reduced caerulein-induced CLDN2 up-regulation compared with wild-type mice. Functionally, Cldn2 KO mice developed more severe disease in both short-term caerulein treatment-induced acute pancreatitis and in a caerulein- and alcohol-treatment induced chronic pancreatitis models. Organoid-based studies revealed CLDN2 is essential for sodium-dependent water transport and adenosine 3',5'-cyclic monophosphate-driven, cystic fibrosis transmembrane conductance regulator-dependent, and 4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid-sensitive fluid secretion. Finally, studies using isolated pancreatic ducts revealed that forskolin-stimulated fluid secretion requires CLDN2. These findings suggest that functional cross talk between paracellular CLDN2 and transcellular transporters is essential for fluid secretion in pancreatic ductal epithelium, protecting against pancreatitis by promoting pancreatic ductal output to limit autodigestion and inflammation.
conclusionsCLDN2 up-regulation is a pathophysiological response to inflammation, and absence of CLDN2 exacerbates disease severity. Modulating pancreatic ductal CLDN2 function represents a potential therapeutic strategy for pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.